AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02759055 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical Decision Support
Description: an EHR-linked, Web-based clinical decision support (CDS) system that identifies patients with prediabetes and provides patients and their primary care providers personalized, evidence-based CDS and follow up to reduce risk of heart attacks or stroke
Study NCT03840759 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: inpatient geriatric consultation team
Description: For the intervention group, a geriatric physician was consulted and recommendations were made by the geriatric consultant after a complete CGA.
Study NCT02081222 — intervention group
Intervention type: PROCEDURE
Intervention: surgery for congenital heart disease with cardiopulmonary bypass
Description: surgery for congenital heart disease with cardiopulmonary bypass
Study NCT02780830 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2014
Description: AZD2014 will be supplied as oral tablets. AZD2014 will be taken orally twice per day on an intermittent dosing schedule, 2 days on and 5 days off of each week.
Study NCT02780830 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Ibrutinib will be provided in hard gelatin capsules in opaque high-density polyethylene bottles. On days of AZD2014 dosing, ibrutinib will be taken with the morning dose of AZD2014.
Study NCT03299790 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: high-intensity interval exercise training (HIIT)
Description: This program includes 24 weeks of exercise training and is divided in different phases (phase 1: week 1-2, equal to the MIT group, phase 2: week 3-6, 6 bouts of high-intensity exercise, phase 3: week 7-12, 7 bouts of high-intensity exercise, phase 4: week 13-24, 8 bouts of high-intensity exercise). The exercise training program consists of 3 exercise sessions per week (for 6 months).
Study NCT03299790 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: moderate-intensity exercise training (MIT)
Description: This program includes 24 weeks of exercise training and is not devided in phases. The exercise training program consists of 3 endurance exercise sessions per week (for 6 months). The total exercise volume equals the exercise volume of the HIIT group.
Study NCT00161395 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Instruction in the Creighton Model Fertility Care System
Description: Instruction in the Creighton Model Fertility Care System.
Study NCT02587585 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Feedback against tailored target
Description: Participants will wear a smart watch every weekday for nine hours during in-patient rehabilitation to monitor activity levels while receiving their usual care. In the active group, the watch will summate activity movement in two hour epochs and the target for the day for that epoch is the activity in the same epoch 24 hours earlier, plus 5%. During an epoch the patient is shown progress towards the target at at the end of an epoch, they will see their final process towards target for that epoch.
Study NCT02587585 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: No feedback
Description: Participants will wear a smart watch every weekday for nine hours during in-patient rehabilitation to monitor activity levels while receiving their usual care. However the watch face will simply show which epoch a person is in. The watch will collect the activity in exactly the same way over the day.
Study NCT00694252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib
Description: Patients will receive lapatinib monotherapy 1500 mg/day for a period of at least one month depending on their response and the clinical status of their disease.
Study NCT01522287 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Computer-Assisted Cognitive Behavior Therapy (BT STEPS)
Description: BT STEPS is a computer-assisted self help treatment for OCD. Clients work through the program at their own pace.
Study NCT04540341 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mulligan mobilization
Description: Mulligan mobilization technique will be apply.
Study NCT04540341 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Core stabilization
Description: Core stabilization technique will be apply.
Study NCT04540341 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional therapy
Description: Conventional therapy exercise will be apply.
Study NCT01826136 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acapella device
Study NCT03572725 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Gas tamponade
Description: Removal of intraocular fluid and replacement with intraocular tamponade. No restriction of postoperative positioning with exception to the supine position. A tennis ball is attached to the back of patients at night. This measure will assists them in avoiding the nocturnal supine position.
Study NCT03572725 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Air tamponade
Description: Removal of intraocular fluid and replacement with intraocular tamponade. No restriction of postoperative positioning with exception to the supine position. A tennis ball is attached to the back of patients at night. This measure will assists them in avoiding the nocturnal supine position.
Study NCT01753661 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Linguistic Feedback Report
Description: Throughout the study, parents will complete 16 total LENA recordings. The feedback report will include information on the parent's previous LENA recording(s), including the Adult Word Count (AWC), Conversational Turns (CTC), and TV Time (TVT). Parents in the treatment group will receive feedback reports for the baseline and 10 weekly recordings. Feedback reports will not be offered for the follow-up recordings
Study NCT01753661 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multimedia Education Sessions
Description: Treatment group parents will receive 10 weekly home visit sessions (e.g. the ASPIRE Program) with an interventionist during which time they will review multimedia education modules. The sessions include feedback report review, module discussion, video modeling, and goal setting activities. The education modules provide parents with information on supporting the development of listening and spoken language for children with hearing loss.
Study NCT01753661 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: EI-As-Usual
Description: The EI-as-usual condition will parallel the treatment condition. Families in the EI-as-usual condition will continue to receive their usual therapy. They will not participate in Project ASPIRE home visits or receive feedback on their recordings. Families in this group will complete the same assessments as the families in the treatment group.
Study NCT04164251 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Screening mammography
Description: The purpose of the study was to evaluate the feasibility of securing inpatient breast cancer screening mammograms for non-adherent hospitalized women prior to hospital discharge.
Study NCT01630863 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy
Description: Photodynamic therapy is performed using verteporfin. Full dose of verteporfin is infused for 10 minutes, followed by laser delivery at 15 minutes from the start of infusion. Different light dose of PDT is applied to the patients at 50%, 40% and 30% of the full energy based on TAP study. The area of irradiation is set to the abnormal choroidal vascular hyperpermeability on ICGA corresponding to the leaking area on FA.
Study NCT00731562 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline Tartrate Controlled Release
Description: A single, 2.4 mg dose of a varenicline controlled release tablet administered orally under fasted conditions
Study NCT00731562 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline Tartrate Controlled Release
Description: A single, 2.4 mg dose of a varenicline controlled release tablet administered orally under fed conditions
Study NCT03937908 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2g Centella asiatica water extract product
Description: 2g of Centella asiatica water extract (CAW) in a standardized product containing excipients to improve palatability, color matching and dispersability. The product (CAP) is a powder which will be dissolved in 10-12 ounce of water and consumed by mouth once on an empty stomach.
Study NCT03937908 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4g Centella asiatica water extract product
Description: 4g of Centella asiatica water extract (CAW) in a standardized product containing excipients to improve palatability, color matching and dispersability. The product (CAP) is a powder which will be dissolved in 10-12 ounce of water and consumed by mouth once on an empty stomach.
Study NCT04441957 — intervention group
Intervention type: DEVICE
Intervention: Endovenous Mechano- Chemical Ablation
Description: The Flebogrif™ catheter (Balton® Sp. z o.o., Warsaw, Poland) represents endoluminal Non Thermal Non Tumescent devices designed to cause occlusion (fibrosis) of the target vein through the combined mechanical and chemical damage to its endothelial lining with retractable cutters and foamed sclerosant.
Study NCT04182269 — intervention group
Intervention type: OTHER
Intervention: Measurement of functional exercise capacity
Description: The Glittre Activities of Daily Living (ADL) Test was used to evaluate functional exercise capacity.
Study NCT04114331 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual therapy and exercise
Description: Manual therapy consisting of soft tissue and joint mobilization to gain mobility. Therapeutic exercise was active motion and resisted motion to gain motor control and motor coordination in the new range.
Study NCT04645901 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug: SYHA1805 tablets
Description: Oral tablets of SYHA1805 with several doses
Study NCT04645901 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral tablets of placebo with matching several doses
Study NCT02588716 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Terlipressin
Description: Terlipressin will be given as an intravenous injection of 2μg/kg/h to be continued throughout the surgery and weaned off over four hours postoperatively.
Study NCT02588716 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: Same volumes of normal saline infusion, throughout the operation then gradually withdrawn over 4 hours.
Study NCT01123941 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Typherix
Description: 1 dose, 0.5 mL containing 25 mcg of Vi polysaccharide
Study NCT01123941 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NVGH Vi-CRM197
Description: 1 dose of 0.5 mL containing 25 mcg of Vi-CRM
Study NCT05336396 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BMI
Description: Longitudinal data will be collected to determine the effectiveness of BMI compared to traditional OHI to maintain and improve periodontal health.
Study NCT04210388 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5718 tablet, Formulation A
Description: Volunteers will receive single doses of AZD5718 tablet, Formulation A under fasted conditions. The dose will be administered with 240 mL (8 fluid ounces) of non-carbonated water after an overnight fast of at least 10 hours.
Study NCT04210388 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5718 tablet, Formulation B
Description: Volunteers will receive single doses of AZD5718 tablet, Formulation B under fasted conditions. The dose will be administered with 240 mL (8 fluid ounces) of non-carbonated water after an overnight fast of at least 10 hours.
Study NCT04210388 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5718 tablet, Formulation C
Description: Volunteers will receive single doses of AZD5718 tablet, Formulation C under fasted conditions. The dose will be administered with 240 mL (8 fluid ounces) of non-carbonated water after an overnight fast of at least 10 hours.
Study NCT00161395 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Preconception advice
Description: Preconception advice for diet and frequency of intercourse.
Study NCT00920023 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Superparamagnetic Iron Oxide Magnetic Resonance Imaging
Description: Two MRIs will be performed over a two day period. The second scan will be done 48 hours after intravenous infusion of ferumoxytol
Study NCT00578721 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: 325 mg taken daily with an arginine-restricted diet
Study NCT04210388 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5718 tablet, Formulation D
Description: Volunteers will receive single doses of AZD5718 tablet, Formulation D under fasted conditions. The dose will be administered with 240 mL (8 fluid ounces) of non-carbonated water after an overnight fast of at least 10 hours.
Study NCT04210388 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AZD5718 film-coated tablet, Reference treatment
Description: Volunteers will receive single doses of AZD5718 film-coated tablet, Reference treatment under fasted conditions. The dose will be administered with 240 mL (8 fluid ounces) of non-carbonated water after an overnight fast of at least 10 hours.
Study NCT04684628 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-PSMA PET/CT
Description: Administration of 68Ga-PSMA-11 followed by a PET/CT scan at 45 min after injection.
Study NCT03444948 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EUS-RFA using Habib Tm as a probe
Description: 3 EUS-RFA interventions at 1-month interval
Study NCT03444948 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: EUS
Description: Standard intervention
Study NCT01891565 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Feedback
Study NCT03575299 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: The adoptive treatment of allogeneic γδT cells
Description: Allogeneic γδT cells will be administered to patients with MDR-TB every two weeks, for 12 times in a total of 6 months.
Study NCT03575299 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: No allogeneic γδT cells will be administered to patients with MDR-TB.
Study NCT03575299 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Conventional treatment
Description: Patients will be treated with anti-tuberculosis drugs throughout the entire process of the study.
Study NCT03575299 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conventional treatment
Description: Patients will be treated with anti-tuberculosis drugs throughout the entire process of the study.
Study NCT02992977 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AutoSynVax™ vaccine
Description: AutoSynVax™ vaccine + QS-21 Stimulon® adjuvant
Study NCT00614523 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is supplied in a 5 mL single use glass vial as a sterile, white, preservative-free, lyophilized powder.
Study NCT00614523 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Romiplostim
Description: Romiplostim is supplied in a 5 mL single use glass vial as a sterile, white, preservative-free, lyophilized powder.
Study NCT03721692 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RIC
Description: The patients will use RIC everyday for three months, 5 cycles 5min ischemic-5min reperfusion each day.
Study NCT00616616 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: single incision laparoscopic surgery
Description: Surgery will be performed with ine laparoscopic incision
Study NCT00582504 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VEE TC-83
Description: Subjects will receive a single 0.5 mL dose by subcutaneous route in the upper outer aspect of arm
Study NCT00630721 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: IFNbeta-1b
Description: no drug was given under study arm. only blood draw on patients already on IFNbeta-1b.
Study NCT01310634 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Comprehensive intervention
Description: Parents of hospitalized neonates received comprehensive intervention program,including parent educational-behavioral intervention program, effective doctor/nurse parent communication,regularly visit the neonatal ward and care the hospitalized neonates under the guidance of a doctor.
Study NCT01310634 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Comprehensive intervention
Description: Parents of hospitalized neonates received comprehensive intervention program,including parent educational-behavioral intervention program, effective doctor/nurse parent communication,regularly visit the neonatal ward and care the hospitalized neonates under the guidance of a doctor.
Study NCT02041143 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Milk protein
Description: Study product will provide 25 g of protein to subjects.
Study NCT04268992 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Long-term exercise
Description: All patients randomised to long-term exercise will perform exercise training at least three times a week for three months. The exercise is supervised and individualised.
Study NCT01765595 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DDI+
Study NCT02041143 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Product with no protein
Study NCT02349919 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Procaterol
Description: Procaterol 25 micrograms/tablet, 1 tablet twice daily for 4 weeks
Study NCT02087501 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Horizon™ Abdominal Aortic Aneurysm Stent Graft System
Description: All patient eligible to undergo stent implantation will receive the Horizon™ Abdominal Aortic Aneurysm Stent Graft System and its designated Delivery System.
Study NCT04330365 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Whole Health Team (WHT) Intervention Arm, Primary Care Group Education (PC-GE) Intervention Arm, Usual Primary Care (UPC) Arm
Description: Participants will be randomly assigned at the individual level to either WHT, PC-GE or Usual Primary Care, stratified by site, sex, and use of prescribed opioids for chronic pain. The follow-up period for the three arms will be 12 months. The primary outcome is change in pain interference. Secondary outcomes include change in pain intensity, functioning, quality of life, changes in use of pain medications, including opioids (if applicable) and changes in nonpharmacological pain self-management activities. After the baseline assessment, masked telephone assessments will be administered to participants at 3, 6, 9, and 12 months.
Study NCT04330365 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Whole Health Team (WHT) Intervention Arm, Primary Care Group Education (PC-GE) Intervention Arm, Usual Primary Care (UPC) Arm
Description: Participants will be randomly assigned at the individual level to either WHT, PC-GE or Usual Primary Care, stratified by site, sex, and use of prescribed opioids for chronic pain. The follow-up period for the three arms will be 12 months. The primary outcome is change in pain interference. Secondary outcomes include change in pain intensity, functioning, quality of life, changes in use of pain medications, including opioids (if applicable) and changes in nonpharmacological pain self-management activities. After the baseline assessment, masked telephone assessments will be administered to participants at 3, 6, 9, and 12 months.
Study NCT01905254 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Transient elastography (TE)
Description: TE and minilaparoscopic guided liver biopsy were performed by physicians blinded to the results the other within a period of less than 3 months.
Study NCT01905254 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Liver biopsy
Description: Minilaparoscopic guided liver biopsy was performed within a period of 3 months of Transient Elastography
Study NCT00142922 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breaking Down Barriers
Description: completed
Study NCT00142922 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Breaking Down Barriers
Description: completed
Study NCT01679457 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ACT-Focused ERP
Study NCT01268202 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pravastatin
Description: Pravastatin 40mg/day during 12 months
Study NCT00737880 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Organ perfusion during pancreas procurement
Description: Usage of UW or HTK perfusion solution during in situ abdominal organ perfusion in multi-organ procurement
Study NCT02995850 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CRS+HIPEC
Description: 1. Ib~   * Dose-escalation of intraperitoneal paclitaxel will follow a modified 3 + 3 dose escalation procedure.~2. II~   ① CRS If PCI \<12, CRS will be performed by gastrectomy with D2-lymphadenectomy and resection of any involved adjacent structures.~   If PCI≥12, instead of CRS, 3 times of IP paclitaxel +cisplatin and oral S-1 chemotherapy every 3 weeks, and then PCI \<12, CRS will be done.~   ② Extensiveintraperitoneal lavage Peritoneal lavage after CRS will be done with 10 L before HIPEC.~   ③ HIPEC Following surgery HIPEC will be performed using CDDP (60 mg/m2) and PTX (P2RD mg/m2). IP chemotherapy will be performed.~   ④ Post-operative intraperitoneal chemotherapy Postoperative chemotherapy will be done 8 cycles of IP paclitaxel+ cisplatin and oral S-1 after 4 weeks.